La Bella Saverio, Gupta Latika, Venerito Vincenzo
UOC Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Pediatric Rheumatology Unit, "G. D'Annunzio" University of Chieti, Chieti, Italy.
Curr Opin Rheumatol. 2025 Sep 1;37(5):296-307. doi: 10.1097/BOR.0000000000001087. Epub 2025 Mar 11.
There is a growing interest in the applications of artificial intelligence in pediatric rheumatology. Although concerns with training datasets, ethical considerations, and the need for a major utilization of explainable artificial intelligence are still ongoing challenges, significant advancements have been made in recent years. In this review, we explore the most recent applications of artificial intelligence in pediatric rheumatology, with a special focus on machine learning models and their outcomes.
Supervised and unsupervised machine learning models have been largely employed to identify key biomarkers, predict treatment responses, and stratify patients based on disease presentation and progression. In addition, innovative artificial intelligence driven imaging tools and noninvasive diagnostic methods have improved diagnostic accuracy and emerged as encouraging solutions for identifying inflammation and disease activity. Large language models have been utilized for patient-based questions with promising results. Nevertheless, critical examination and human oversight are still crucial in interpreting artificial intelligence's outputs.
Artificial intelligence is revolutionizing pediatric rheumatology by improving diagnosis and disease classification, patient stratification and personalized treatment. However, we are only at the beginning, and the adventure has just begun.
人工智能在儿科风湿病学中的应用正受到越来越多的关注。尽管训练数据集、伦理考量以及对可解释人工智能的大量应用需求等问题仍是持续存在的挑战,但近年来已取得了重大进展。在本综述中,我们探讨了人工智能在儿科风湿病学中的最新应用,特别关注机器学习模型及其成果。
监督式和非监督式机器学习模型已被广泛用于识别关键生物标志物、预测治疗反应以及根据疾病表现和进展对患者进行分层。此外,创新的人工智能驱动的成像工具和非侵入性诊断方法提高了诊断准确性,并成为识别炎症和疾病活动的令人鼓舞的解决方案。大型语言模型已被用于解答基于患者的问题,取得了有前景的结果。然而,在解释人工智能的输出时,批判性审查和人为监督仍然至关重要。
人工智能正在通过改善诊断和疾病分类、患者分层和个性化治疗,彻底改变儿科风湿病学。然而,我们才刚刚开始,这场冒险才刚刚起步。